Last update 23 May 2025

Tocilizumab-aazg

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Tocilizumab Biosimilar (Fresenius Kabi Deutschland GmbH), Tocilizumab biosimilar(Fresenius Kabi), 托珠单抗生物类似药(Fresenius Kabi Deutschland GmbH)
+ [2]
Target
Action
antagonists
Mechanism
IL-6RA antagonists(Interleukin-6 receptor alpha subunit antagonists)
Inactive Indication-
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Juvenile Idiopathic Arthritis
Canada
11 Oct 2024
COVID-19
European Union
15 Sep 2023
COVID-19
Iceland
15 Sep 2023
COVID-19
Liechtenstein
15 Sep 2023
COVID-19
Norway
15 Sep 2023
Cytokine Release Syndrome
European Union
15 Sep 2023
Cytokine Release Syndrome
Iceland
15 Sep 2023
Cytokine Release Syndrome
Liechtenstein
15 Sep 2023
Cytokine Release Syndrome
Norway
15 Sep 2023
Giant Cell Arteritis
European Union
15 Sep 2023
Giant Cell Arteritis
Iceland
15 Sep 2023
Giant Cell Arteritis
Liechtenstein
15 Sep 2023
Giant Cell Arteritis
Norway
15 Sep 2023
Oligoarticular Arthritis
European Union
15 Sep 2023
Oligoarticular Arthritis
Iceland
15 Sep 2023
Oligoarticular Arthritis
Liechtenstein
15 Sep 2023
Oligoarticular Arthritis
Norway
15 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis
European Union
15 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis
Iceland
15 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis
Liechtenstein
15 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
interleukin-6
-
djhioxytpx(wvmxmlgmpm) = fboyesxrct qveffirode (lhxejmvlou )
Positive
05 Jun 2024
Not Applicable
-
jexrplxaor(zalfjuhcpr) = espjesihcm dhteizvdin (eixbwcsftr )
Positive
31 May 2023
EU-approved tocilizumab
jexrplxaor(zalfjuhcpr) = dyqsngejlk dhteizvdin (eixbwcsftr )
Phase 3
604
rqmdfyrgyu = ycftjwvkmi xbethyzeyr (vlqjjltmxl, jjdmqnvvzc - rrzpkqfqoe)
-
24 Oct 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free